Luye Pharma Group (2186) Stock Overview
Develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2186 from our risk checks.
2186 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Luye Pharma Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.82 |
| 52 Week High | HK$3.92 |
| 52 Week Low | HK$1.67 |
| Beta | 0.80 |
| 1 Month Change | 94.90% |
| 3 Month Change | 60.50% |
| 1 Year Change | 30.82% |
| 3 Year Change | 59.17% |
| 5 Year Change | -26.40% |
| Change since IPO | -42.99% |
Recent News & Updates
Recent updates
It's Probably Less Likely That Luye Pharma Group Ltd.'s (HKG:2186) CEO Will See A Huge Pay Rise This Year
May 21
Investors Appear Satisfied With Luye Pharma Group Ltd.'s (HKG:2186) Prospects
Feb 11Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Dec 22Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares
Sep 25Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?
Aug 29Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors
Jun 19We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed
May 21Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden
Apr 26Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?
Feb 29Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S
Jan 09Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt
Dec 19A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)
Nov 24Is Luye Pharma Group (HKG:2186) A Risky Investment?
Sep 12Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price
Aug 17Is Luye Pharma Group (HKG:2186) Using Too Much Debt?
May 10We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt
Sep 20Shareholder Returns
| 2186 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 35.9% | 5.0% | 3.1% |
| 1Y | 30.8% | 43.7% | 26.3% |
Return vs Industry: 2186 underperformed the Hong Kong Pharmaceuticals industry which returned 43.7% over the past year.
Return vs Market: 2186 exceeded the Hong Kong Market which returned 26.3% over the past year.
Price Volatility
| 2186 volatility | |
|---|---|
| 2186 Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 7.8% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in HK Market | 14.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2186 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2186's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 5,150 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine.
Luye Pharma Group Ltd. Fundamentals Summary
| 2186 fundamental statistics | |
|---|---|
| Market cap | HK$14.37b |
| Earnings (TTM) | HK$516.09m |
| Revenue (TTM) | HK$6.63b |
Is 2186 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2186 income statement (TTM) | |
|---|---|
| Revenue | CN¥6.06b |
| Cost of Revenue | CN¥2.02b |
| Gross Profit | CN¥4.04b |
| Other Expenses | CN¥3.57b |
| Earnings | CN¥471.89m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 66.72% |
| Net Profit Margin | 7.79% |
| Debt/Equity Ratio | 65.1% |
How did 2186 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 21:12 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Luye Pharma Group Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |